Lung Cancer News

The addition of ramucirumab to gemcitabine significantly improved survival among patients with malignant pleural mesothelioma, according to randomized phase 2 study results presented during the ASCO20 Virtual Scientific Program.

Prior use of chemotherapy appeared associated with an increased risk for death among patients with lung or other thoracic cancers and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

This month, Healio announced the launch of its latest podcast, Oncology Overdrive.

The FDA expanded the approval of nivolumab plus ipilimumab for treatment of lung cancer, according to the agents’ manufacturer.

The FDA approved brigatinib for first-line treatment of adults with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.

The FDA expanded the approval of atezolizumab to include first-line monotherapy of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression.

The FDA approved nivolumab plus ipilimumab for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1.

People who quit smoking prior to a lung cancer diagnosis demonstrated considerably reduced risk for death due to all causes compared with those who continued to smoke, according to study results scheduled for presentation during the ASCO20 Virtual Scientific Program.

The FDA approved selpercatinib for the treatment of patients with one of three types of tumors that have RET alterations.